Mats Jerkeman
141 – 160 of 171
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
(
- Contribution to journal › Article
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
(
- Contribution to journal › Article
- 2008
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142(
- Contribution to journal › Published meeting abstract
-
Mark
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Nuclear expression of the Non-B Cell Lineage Sox11 Transcription Factor Identifies Mantle Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
(
- Contribution to journal › Article
-
Mark
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.
(
- Contribution to journal › Published meeting abstract
-
Mark
Burkitt's lymphoma: Comparison of 2 nationwide population-based lymphoma registries
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.131-131(
- Contribution to journal › Published meeting abstract
-
Mark
Sox11, a non-B cell lineage transcription factor, is overexpressed in mantle cell lymphoma
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.172-173(
- Contribution to journal › Published meeting abstract
-
Mark
Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
B cell lymphomas express CX(3)CR1 a non-B cell lineage adhesion molecule.
(
- Contribution to journal › Article
- 2007
-
Mark
Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN
(
- Contribution to journal › Article
-
Mark
Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers
(
- Contribution to journal › Article
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
- 2006
-
Mark
Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy
(
- Contribution to journal › Article
- 2005
-
Mark
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma
(
- Contribution to journal › Article
-
Mark
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
(
- Contribution to journal › Article
- 2004
-
Mark
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.
(
- Contribution to journal › Article